Q1 earnings: 3 things to know

Medtronic announced first-quarter FY25 financial results on Tuesday. Here are three things to know:

A strong start

Our innovative technologies fueled 5.3% organic revenue growth during the first quarter. Notable growth drivers included our Percept™ RC deep brain stimulator, transcatheter aortic heart valves (TAVR), and our MiniMed™ 780G automated insulin delivery (AID) system that treats diabetes.

Innovating for the future

We launched several therapies that will build on our momentum - and benefit patients. Those include Inceptiv™, an advancement in the treatment of chronic pain through spinal cord stimulation therapy, and Evolut™ FX+ TAVR, a therapy for patients with severe aortic stenosis.

Raising our guidance

Following our strong first-quarter performance, we're raising our guidance for the full fiscal year. We now expect organic revenue growth of 4.5% to 5%, and non-GAAP diluted earnings per share of $5.42 to $5.50.

L009-08192024

Related content